Kornimate/medical-research-clean huggingface dataset:
serum ceramides level in systemic lupus erythematosus (sle) patients as a novel marker for renal impairment

Conditions: Systemic Lupus

Summary: 1. estimation of serum ceramides level in sle patients as anovel marker for renal impairment 2. correlation serum ceramides level with histological classification of ln,c3,c4,ana,anti ds dna ,crp ,esr , egfr , creatinine /protein ratio 3. follow up estimation of ceramides level in ln patients after 3 cycles of treatment

systemic lupus erythrematosus (sle) is an autoimmune disease with increasing prevalence and incidence , the clinical manifestation is multifaceted and targets the musculoskeletal system, the skin and different organs like lung and kidney from 30-80% of sle patients develop lupus nephritis (ln) which often leads to chronic kidney disease (ckd) and end-stage renal disease (esrd) and is associated with an overall poor prognosis and high mortality diagnosis of ln is made by kidney biopsy, which still remains the gold standard histological evaluation distinguish between different stages of ln upon morphological changes within the kidney . however, noninvasive methods to diagnose and guide ln therapy are currently not established in the clinic. on the other hand, an early diagnosis is important for the therapeutic success and thereby lowers the risk of esrd in this context, classical clinical markers for renal dysfunction are insufficient for an early assessment of the need for renal biopsies and subsequently to decide about the optimal therapy. even though traditional biomarkers like antids dna antibodies and complement deficiency are widely accepted as diagnostic instruments to assess disease activity, their specificity is rather low, and they appear to be more suitable to confirm diagnosis of sle and ln in an already likely clinical setting ceramides are a family of waxy lipid molecules ,composed of sphingosine and fatty acide ,found in high concentration with in the cell membrane of eukaryocyte cells, since they are component lipids that make up sphingomyelin, one of the major lipids in the lipid bilayer ceramides and other sphingolipids found in cell membrane were purely supporting structural elements,also participate in variety of cellular signaling, regulating differentiation, proliferation, programmed cell death(pcd) sphingolipids are a heterogenous group of lipids with more than 400 single compounds formed by structural and chemical modifications of a sphingosine backbone recent studies reveal that blood sphingolipids not only have important signaling properties but also serve as biomarkers in various renal disease patyna etal in 2019 concluded that ceramides in blood could act as potent biomarker for renal impairment in patient

Eligibility criteria:
inclusion criteria: * forty five patients will sle with and without renal impairment diagnosed as sle according to slicc classification criteria for sle exclusion criteria: * malignant tumor ,infectious diseases, alzheimer disease ,type 2 diabetes mellitus vitamin d intaker, obesty , cardiovascular disease (htn,hf ,ischemic heart disease)
crs questionnaire validation project

Conditions: Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps

Summary: the 'crs validation project' consists of a joint effort of 32 medical centers in europe, the usa, and south africa to carry out the validation of 2 novel questionnaires designated to measure self-perceived severity and control of chronic rhinosinusitis (with or without nasal polyps). this study will validate translated versions of the same set of questionnaires simultaneously in the centers involved after recruiting a total of 1000 patients, while data collection, statistical analysis, and creation of the study report will be carried out by the statistical department of the university of leuven. patients will be recruited from the regular ent practice of their hospital to minimize the complexity of the study.

the objectives of this study are as follows: * validation of two new questionnaires with the aim of measuring the current perceived condition of a patient with chronic rhinosinusitis in terms of control and severity. * validation of these questionnaires in routine medical settings. * evaluation of the results of these questionnaires in comparison with other tools currently available.

Eligibility criteria:
inclusion criteria: * patient capable of giving informed consent * diagnosis of chronic rhinosinusitis with or without nasal polyposis according to the epos guidelines * no recent sinus surgery (within the last three months) exclusion criteria: * not capable of giving informed consent * no crs * recent sinus surgery (within the last three months)
detecting transitional cell carcinoma from haematuria

Conditions: Transitional Cell Carcinoma

Summary: to validate elisas for the detection of urinary tissue factor (tf) in patients suspected of having bladder cancer.

the effective diagnosis of transitional cell carcinoma (tcc), the most common form of bladder cancer, is often quite challenging, due to a lack of disease-specific symptoms. detecting tcc early is crucial to increase the chances of a cure. cystoscopy, which is currently the standard test used for urothelial cancer diagnosis, is an invasive and relatively expensive procedure but, while several potential markers in urine have been studied with the goal of replacing cystoscopy, no urinary marker alone or in combination with others has shown sufficient accuracy. in this study, levels of tissue factor (tf) isoforms will be measured by elisa in urine samples collected from patients referred to the haematuria clinic with visible or microscopic haematuria. these values will be linked to the subsequent diagnosis of each patient, and used to assess the accuracy of the elisas in detecting tcc when compared to standard cystoscopy.

Eligibility criteria:
inclusion criteria: * capable of giving written informed consent * age ≥18 years * referral to haematuria clinic (gross or microscopic haematuria) exclusion criteria: * inability to provide written informed consent * previous radiotherapy to the bladder (e.g. prostate cancer) * active urinary tract infection (patients may be re-approached at later opportunity when urinary infection is cleared and haematuria persists) * current or planned treatment with neoadjuvant chemotherapy or radiotherapy * other known malignant condition, either active or in complete remission ≤5 years * hiv, hepatitis c, or any other known communicable disease
mechanical versus manual chest compression

Conditions: Cardiac Arrest; Cardiopulmonary Resuscitation

Summary: in this study, the investigators compared mechanical and manual chest compressions in out-of-hospital cardiac arrest cases.

in this study, the investigators retrospectively analyzed resuscitations performed over a 2-year period and compared manual and mechanical chest compressions in terms of return of spontaneous circulation, 30-day survival, and hospital discharge parameters.

Eligibility criteria:
inclusion criteria: over 18 age cardiac arrest cases out-of-hospital arrest exclusion criteria: \<18 age

Keywords: cardiopulmonary resuscitation chest compression manuel mechanical
efficacy of chemotherapy alone in patients with poor-differentiated early-stage cervical cancer

Conditions: Cervical Cancer

Summary: this study is aimed to enroll patients with early-stage cervical cancer (figo 2018 ib1-ib2) who undergo radical hysterectomy and the postoperative pathology doesn't meet sedlis criteria or the "four-factor" model but with poorly differentiated squamous/adenocarcinoma/adenosquamous carcinoma. patients will be randomly divided into two groups in a 1:1 ratio. the experimental group received 4 courses of paclitaxel and cisplatin (once every 3 weeks) for adjuvant chemotherapy within 4 weeks after surgery, while the control group don't not receive any adjuvant therapy but only received regular follow-up. the disease status of all patients will be evaluated within 4 weeks after the end of all treatment and every 12 weeks thereafter, including gynecological examination, laboratory indicators, imaging evaluation, and the prognosis of the two groups will be compared.


Eligibility criteria:
inclusion criteria: 1. the age of patients is 18-70 years old. 2. patients with cervical cancer who undergo radical hysterectomy and pelvic lymphadenectomy as initial treatment (including laparoscopic and abdominal surgery). 3. clinical stage is ib1-ib2 according to figo 2018 stage. 4. the postoperative pathological type is squamous cell carcinoma/adenocarcinoma/adenosquamous carcinoma. 5. the degree of tumor differentiation is poorly differentiated. 6. do not meet the sedlis criteria or the four-factor model, but meet one of the following factors: ① lvsi (+); ② tumor diameter \> 2cm; ③ depth of cervical stromal invasion \> superficial 1/3; (4) adenocarcinoma. exclusion criteria: 1. postoperative pathological stage ≥iia (according to the 2018 figo staging system). 2. patients with the following high risk factors: ① lymph node metastasis; ② parametrial involvement; ③ positive surgical margin; ④ vaginal involvement. 3. patients received neoadjuvant chemotherapy. 4. there was evidence of distant metastasis on preoperative imaging examination. 5. patients received postoperative radiotherapy. 6. history of abdominal or pelvic radiotherapy. 7. patients with other malignant tumors. 8. patients with missing or partially missing clinical, surgical, and pathological data were lost to follow-up.

Keywords: early-stage chemotherapy alone poor differentiation
safety and performance study of the cypass system applier model 241

Conditions: Open Angle Glaucoma (OAG)

Summary: this is a retrospective chart review of cases in which the cypass micro-stent was implanted using the model 241 applier. the objective of this study is to characterize and evaluate the safety of the model 241 applier when used for cypass micro-stent implantation.


Eligibility criteria:
inclusion criteria: 1. diagnosis of oag 2. cypass micro-stent implantation (using the cypass system 241) following uncomplicated phacoemulsification cataract removal and intraocular lens implantation exclusion criteria: 1. diagnosis of acute angle closure, traumatic, congenital, malignant, uveitic or neovascular glaucoma 2. prior incisional glaucoma surgery
a study of avastin (bevacizumab) in combination with chemotherapy in chinese patients with metastatic colorectal cancer.

Conditions: Colorectal Cancer

Summary: this 2 arm study will assess the efficacy and safety of avastin in combination with irinotecan + 5-fluorouracil/folinic acid, versus irinotecan + fluorouracil/folinic acid alone, as first line treatment in chinese patients with metastatic colorectal cancer. patients will be randomized 2:1 to receive 6-weekly cycles of avastin (5mg/kg iv every 2 weeks) + irinotecan 125mg/m2 iv / leucovorin 20mg/m2 iv / fluorouracil 500mg/m2 iv weekly for 4 weeks, or 6-weekly cycles of irinotecan 125mg/m2 iv / leucovorin 20mg/m2 iv / fluorouracil 500mg/m2 iv weekly for 4 weeks. the anticipated time on study treatment is until disease progression, and the sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, \>=18 years of age; * histologically confirmed adenocarcinoma of the colon or rectum, with metastatic disease; * \>=1 measurable lesion; * ecog performance status of \<=1. exclusion criteria: * prior systemic therapy for advanced or metastatic disease; * adjuvant or neo-adjuvant treatment for non-metastatic disease in past 6 months; * other malignancy within past 5 years, except cured basal cell cancer of skin or cured cancer in situ of cervix; * clinically significant cardiovascular disease in past 6 months.
tns for treating major depressive disorder in the elderly

Conditions: Major Depressive Disorder; Elderly

Summary: this is a phase ii, open-label clinical trial. this clinical trial has as primary objective to evaluate changes in eeg of a trigeminal nerve stimulation (tns) treatment protocol for elderly patients with moderate / severe depressive episode.


Eligibility criteria:
inclusion criteria: 1. patients between 65 and 99 years 2. patients with a diagnosis of depression according to the scid 3. score greater than or equal to 18 on the hamilton rating scale 17-item version (equivalent to moderate or severe depressive episode) 4. agreement to participate in the study as recommended in the ic. exclusion criteria: 1. patients with psychiatric indication for hospitalization 2. patients with psychiatric comorbidity 3. patients with a diagnosis of personality disorder 4. presence of severe neurological or medical diseases such as neoplasms in activity, neurodegenerative diseases and chronic diseases uncompensated.
unveiling patient experiences in testicular cancer clinical trials

Conditions: Testicular Cancer

Summary: clinical research participation has historically been heavily biased toward specific demographics. several people will be invited to enroll in this study so that it may collect a variety of data about testicular cancer clinical study experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal. people with testicular cancer who are invited to take part in medical research will benefit from the analysis of the data.


Eligibility criteria:
inclusion criteria: * aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed * diagnosis of testicular cancer * no prior treatment for testicular cancer exclusion criteria: * has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial * enrolled in another research study * inability to provide written informed consent

Keywords: testicular cancer
efficacy and safety of pr022 topical gel to treat mild-to-moderate atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the purpose of this study is to determine whether pr022 topical gels are safe and effective treatments for mild-to-moderate atopic dermatitis (ad).


Eligibility criteria:
inclusion criteria: * male or female subjects 18 to 65 years of age * easi score ≤ 21 at baseline * diagnosis of mild-to-moderate (grade 2 or 3) ad according to the isga scale at baseline * bsa affected by ad: 5% to 20% at start of treatment * willing and able to apply study treatments as directed, comply with study instructions, and commit to attending all visits * willing and able to provide informed consent * use of adequate birth control, if of reproductive potential and sexually active exclusion criteria: * widespread ad requiring systemic therapy * use of any of the following treatments within the specified time periods prior to day 1 * topical medications (topical antibiotics, topical corticosteroids, topical antifungals, topical antihistamines, topical retinoids, topical calcipotriene, tacrolimus, pimecrolimus, or other topical drug products for treatment of ad) or bleach bath within 2 weeks prior to day 1 * systemic agents (cyclosporine, systemic corticosteroids \[oral and injectable; intranasal and inhaled corticosteroids are allowed if use is kept constant during the study\], systemic antibiotics, immunomodulators or immunosuppressive therapies, interferon, cytotoxic drugs \[e.g., methotrexate, cyclophosphamide, azathioprine\], oral retinoids, systemic antifungals, tacrolimus) for the treatment of ad within 4 weeks prior to day 1 * ultraviolet (uv) therapy or use of a tanning booth/parlor within 6 weeks prior to day 1 * biologic therapies within 12 weeks (or 5 half-lives) prior to day 1 * antihistamines within 5 days prior to day 1 \[stable regimens (consistent use ≥ 14 days before day 1) of oral h1 antihistamines for non-ad lesion treatment will be allowed\] * active or potentially recurrent dermatologic condition other than ad that may confound evaluation * congenital ichthyosis (note that subjects with ichthyosis vulgaris are permitted) * known allergy to any ingredients of the investigational product formulation * significant confounding conditions as assessed by investigator * any condition that could interfere with any evaluation in the study * pregnancy or breast feeding * any reason which, in the opinion of the investigator, interferes with the ability of the subject to participate in or complete the trial
impact of triglyceride-glucose index on cardiovascular outcomes in patients presented with minoca

Conditions: Major Cardiovascular Events

Summary: this work was designed to explore the role of the triglyceride-glucose (tyg) index in the prediction of cardiovascular outcomes in patients presented with myocardial infarction with nonobstructive coronary arteries.

acute myocardial infarction (ami) remains the leading causes of high morbidity and mortality worldwide . recently, a distinct population with myocardial infarction with nonobstructive coronary arteries (minoca) has been increasingly recognized because of the widespread use of coronary angiography. minoca occurs in 5%-10% of all ami and they are younger and more often women compared to patients with ami and obstructive coronary artery disease (cad). the underlying causes of minoca are manifold and may include plaque rupture or erosion, thromboembolism, coronary spasm, spontaneous dissection, microvascular dysfunction and supply/demand mismatch. some non-ischemic diseases such as myocarditis may also mimic the presentation of minoca . of note, several studies have found that the prognosis of minoca is not trivial and patients are still at considerable risks for long-term adverse cardiovascular (cv) events despite the optimal secondary prevention treatments . thus, it is of necessity and profound implications to find potential residual risk factors and improve prognosis in minoca population. insulin resistance (ir), a critical mechanism of the pathogenesis of diabetes, not only contributes to the development of cardiovascular diseases (cvd), but also significantly correlates with adverse cv outcomes. additionally, ir often coexists with obesity, hypertension, and dyslipidemia , and all of these are well-known risk factors of cvd. recently, the triglyceride-glucose (tyg) index derived from fasting triglyceride (tg) and fasting blood glucose (fbg) levels has been proposed as a new and valid surrogate indicator of ir . till now, many studies have found that the tyg index is positively correlated with metabolic disorders, arterial stiffness , carotid atherogenesis , coronary artery calcification , and subclinical or symptomatic cad. moreover, growing evidence has showed that the tyg index is an independent predictor of poor cv outcomes in general population and in different cohorts with cad, including patients with ami or acute coronary syndrome (acs) with or without diabetes

Eligibility criteria:
inclusion criteria: * all patients; diagnosed with myocardial infarction with nonobstructive coronary arteries (minoca) * clinical symptoms * ecg : ischemic changes with or without st segment elevation * echocardiograpy : segmental wall motion abnormalities (swma) * positive cardiac enzymes * coronary angiography: insignificant lesions ,the absence of culprit obstructive coronary artery disease (epicardial coronary artery stenosis ≥50%) exclusion criteria: * all non confirmed diagnosis of minoca * cardiac * non-ischemic cardiomyopathies * non-cardiac * pulmonary embolism * stroke * sepsis * ards

Keywords: triglyceride glucose index myocardial infarction minoca
alterra: sapien 3 thv with the alterra adaptive prestent

Conditions: Pulmonary Disease; Transcatheter Pulmonary Valve Replacement (TPVR); Tetralogy of Fallot; Congenital Heart Disease; Pulmonary Regurgitation

Summary: to demonstrate the safety and effectiveness of the edwards alterra adaptive prestent in conjunction with the edwards sapien 3 transcatheter heart valve (thv) system in subjects with a dysfunctional right ventricular outflow tract/pulmonary valve (rvot/pv) who are indicated for treatment of pulmonary regurgitation (pr). following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.


Eligibility criteria:
inclusion criteria: 1. the candidate/candidate's legally authorized representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent. 2. weight is ≥ 20 kg (44 lbs). 3. rvot/pv with moderate or greater pr by tte. 4. rvot/pv proximal and distal landing zone diameter ≥ 27 mm and ≤ 38 mm, and minimum of 35 mm from contractile tissue to lowest pulmonary artery takeoff. exclusion criteria: 1. active infection requiring current antibiotic therapy (if temporary illness, patient may be a candidate 2 weeks after discontinuation of antibiotics). 2. history of or active endocarditis (active treatment with antibiotics) within the past 180 days. 3. leukopenia (wbc \< 2000 cells/μl), anemia (hgb \< 7 g/dl), thrombocytopenia (platelets \< 50,000 cells/μl) or any known blood clotting disorder. 4. inappropriate anatomy for introduction and delivery of the alterra adaptive prestent or the sapien 3 thv. 5. need for concomitant atrial septal defect or ventricular septal defect closure or other concomitant interventional procedures other than pulmonary artery or branch pulmonary artery stenting or angioplasty 6. interventional/surgical procedures within 30 days prior to the alterra or valve implant procedure 7. any planned surgical, percutaneous coronary or peripheral procedure to be performed within the 30 day follow-up from the alterra or valve implant procedure 8. history of or current intravenous drug use 9. major or progressive non-cardiac disease resulting in a life expectancy of less than one year 10. known hypersensitivity to aspirin or heparin and cannot be treated with other antiplatelet and/or antithrombotic medications 11. known hypersensitivity to nitinol, cobalt-chromium, nickel or contrast media that cannot be adequately pre-medicated 12. currently participating in an investigational drug or another device study \[note: trials requiring extended follow up for products that were investigational, but have since become commercially available, are not considered investigational devices.\] 13. positive urine or serum pregnancy test in female patients of child-bearing potential 14. renal insufficiency (creatinine \> 3.0 mg/dl) and/or renal replacement therapy